2020 Position Statement on Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem

This position statement raises awareness about the risks of off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements. This statement distinguishes off-label hormone use from legitimate use for diagnoses such as male hypogonadism, growth hormone deficiency, hypothyroidism, and adrenal insufficiency. Read Position Statement more

2019 Clinical Practice Guideline for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care

This guideline provides recommendations on identification, screening, assessment, diagnosis, and treatment of a range of individuals with various causes of adult growth-hormone deficiency (GHD) and patients with childhood-onset GHD transitioning to adult care. The guideline summarizes current knowledge about the accuracy of available GH–stimulation tests, safety of recombinant human GH (rhGH) replacement, unapproved uses of rhGH related to sports and aging, and new developments such as long-acting GH preparations that use a variety of technologies to prolong GH action.… more

2020 Clinical Practice Guideline for the Diagnosis and Treatment of Postmenopausal Osteoporosis

This guideline provides recommendations to reduce a person's risk of osteoporosis-related fractures and to evaluate, diagnose, and treat osteoporosis in postmenopausal women, based on fracture presence, assessment of fracture risk/probability, measurement of bone mineral density or bone mass, and a patient’s history, among other factors. An update of this guideline is currently in development. DOI: 10.4158/GL-2020-0524SUPPL Read Guideline   Osteoporosis is a worldwide… more

2021 Clinical Practice Guideline for the Use of Advanced Technology in the Management of Persons with Diabetes Mellitus

Advanced diabetes technology can potentially assist persons with diabetes to achieve glycemic targets, improve quality of life, reduce burden of care, offer a personalized approach to self-management, and improve the efficiency of clinical decision-making, among other benefits. This guideline provides recommendations on the efficacy and safety of advanced diabetes technology devices for management of persons with diabetes mellitus, metrics used to aide with the assessment of advanced diabetes technology, and standards for implementation of this technology. DOI: 10.1016/j.eprac.2021.04.008… more

2016 Position Statement on Transculturalization Recommendations for Developing Latin American Clinical Practice Algorithms in Endocrinology

This statement provides recommendations from a workshop in Latin America for incorporating transculturalization factors into guidance for management of diabetes (focusing on glycemic control), obesity (focusing on weight loss), thyroid (focusing on thyroid nodule diagnostics), and bone (focusing on postmenopausal osteoporosis) disorders to assist local experts in creating culturally sensitive and easy-to-implement tools for optimizing endocrine care. Read Position Statement more

2012 Position Statement on Healthcare Disparities

Revision Date 07/30/12 The American Association of Clinical Endocrinologists Policy for the Elimination of Endocrine Healthcare Disparities in the USA Since its inception, the American Association of Clinical Endocrinologists (AACE) has advocated for the finest in endocrine education and state-of-the-art health care delivery without regard to race, ethnicity, gender, age, country of origin, economic status, lifestyle, sexual orientation or domestic living arrangements. We, the members of AACE, our patients, and our corporate partners represent the… more

2017 Position Statement on Adiposity-Based Chronic Disease as a New Diagnostic Term

This position statement outlines new terminology and blueprint for a chronic care model with an advanced diagnostic framework for the comprehensive management of obesity. Adiposity-Based Chronic Disease (ABCD) is a new diagnostic term for obesity that explicitly identifies a chronic disease, alludes to a precise pathophysiologic basis, and avoids the stigmata and confusion related to the differential use and multiple meanings of the term “obesity.” Read Position Statement more

2022 Consensus Statement on Immune Checkpoint Inhibitor-Mediated Endocrinopathies

This consensus statement provides a practical approach for management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies with case scenarios of various clinical manifestations and highlights the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies. The statement summarizes the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies; reviews the clinical presentation of ICI-related endocrinopathies; and discusses the diagnosis and management approaches to endocrinopathies related to ICI therapy. DOI: 10.1016/j.eprac.… more

2017 Position Statement on the Use of Follow-On Biologics and Biosimilars for Endocrine Diseases

This position statement provides guidance on follow-on biologics versus biosimilars, interchangeability and substitution, FDA draft guidance for interchangeability of biosimilars, and clinical application. Read Position Statement more

2020 Consensus Statement on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach

This consensus statement provides a practical approach to management of patients with newly diagnosed adrenocortical carcinoma, as well as follow-up and management of patients with persistent or recurrent disease, including the management of an adrenal mass, presurgical evaluation, surgical approach, pathologic assessment, and other therapeutic modalities, based on individual patient presentation. DOI: 10.4158/DSCR-2020-0567 Read Consensus Statement more